Physician profile
Mohammad J Alam
NPI 1255399622
$5,064.70
in general payments reported to CMS, 2019-2025
17 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $12.57 · 2021: $236 · 2022: $1,037 · 2023: $1,036 · 2024: $1,155 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.89 |
| Education | $233.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.85 | 2021-2025 | Avycaz, Dalvance |
| Merck Sharp & Dohme LLC | $894.78 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Astellas Pharma US INC | $887.29 | 2019-2025 | Cresemba |
| Shionogi INC | $508.93 | 2022-2025 | Fetroja |
| Viiv Healthcare Company | $495.81 | 2021-2025 | Dovato, Cabenuva |
| Paratek Pharmaceuticals, INC. | $372.76 | 2022-2025 | Nuzyra |
| Insmed, INC. | $323.64 | 2020-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $203.81 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Gilead Sciences, INC. | $157.56 | 2022-2025 | Sunlenca, Veklury, Biktarvy |
| La Jolla Pharmaceutical Company | $78.91 | 2024-2025 | Xacduro |
| Theratechnologies INC. | $75.06 | 2022-2023 | Egrifta, Trogarzo |
| Alexion Pharmaceuticals, INC. | $39.96 | 2021-2023 | Soliris |
| Janssen Biotech, INC. | $35.68 | 2021-2022 | |
| Invivyd INC | $34.77 | 2025 | Pemgarda |
| Biomerieux INC | $25.00 | 2025 | Filmarray Torch Module |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $18.64 | 2025 | Rebyota |
| Aimmune Therapeutics, INC. | $17.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.